Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity
Abstract
:1. Introduction
2. Experimental Section
2.1. Materials
2.2. Preparation of Solid Lipid Nanoparticles (SLN)
2.3. Photon Correlation Spectroscopy
2.4. Incorporation of Drugs and Determination of Entrapment Efficiency
2.5. Cell Culture Experiments
2.6. Confocal Microscopy and Flow Cytometry
2.7. Cell Cycle Analysis
2.8. Annexin V- Fluorescein isothiocyanate (FITC)/Propidium Iodide (PI) Double Staining and Flow Cytometry
2.9. In Vitro Cell Cytotoxicity Assay
2.10. Protective Effects of Dexamethasone and Hydrocortisone Loaded-Sln Against Cisplatin
2.11. Statistical Analysis
3. Results
3.1. SLN Characterization
3.2. Uptake of SLN by HEI-OC1 Otic Cells
3.3. Cytotoxicity of SLN–RHO and SLN in HEI-OC1 Cells
3.4. The Effects of Glucocorticoids Alone or Incorporated into SLNs on Hei-Oc1 Cell Viability
3.5. SLN–DEX and SLN–HC Protect Against Cisplatin-Induced Cytotoxicity in HEI-OC1 Cells
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Dasari, S.; Tchounwou, P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fetoni, A.R.; Paciello, F.; Mezzogori, D.; Rolesi, R.; Eramo, S.L.M.; Paludetti, G.; Troiani, D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: The role of curcumin on pSTAT3 and Nrf-2 signalling. Br. J. Cancer 2015, 113, 1434–1444. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization, Deafness and Hearing Loss. Available online: http://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss (accessed on 7 Aug 2018).
- Casares, C.; Ramírez-Camacho, R.; Trinidad, A.; Roldán, A.; Jorge, E.; García-Berrocal, J.R. Reactive oxygen species in apoptosis induced by cisplatin: Review of physiopathological mechanisms in animal models. Eur. Arch. Otorhinolaryngol. 2012, 269, 2455–2459. [Google Scholar] [CrossRef] [PubMed]
- Rivera, T.; Sanz, L.; Camarero, G.; Varela-Nieto, I. Drug delivery to the inner ear: Strategies and their therapeutic implications for sensorineural hearing loss. Curr. Drug. Deliv. 2012, 9, 231–242. [Google Scholar] [CrossRef] [PubMed]
- Marshak, T.; Steiner, M.; Kaminer, M.; Levy, L.; Shupak, A. Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone. Otolaryngol. Neck. Surg. 2014, 150, 983–990. [Google Scholar] [CrossRef] [PubMed]
- El Sabbagh, N.G.; Sewitch, M.J.; Bezdjian, A.; Daniel, S.J. Intratympanic dexamethasone in sudden sensorineural hearing loss: A systematic review and meta-analysis. Laryngoscope 2017, 127, 1897–1908. [Google Scholar] [CrossRef]
- Herr, I.; Ucur, E.; Herzer, K.; Okouoyo, S.; Ridder, R.; Krammer, P.H.; von Knebel Doeberitz, M.; Debatin, K.-M. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003, 63, 3112–3120. [Google Scholar]
- Özel, H.E.; Özdoğan, F.; Gürgen, S.G.; Esen, E.; Genç, S.; Selçuk, A. Comparison of the protective effects of intratympanic dexamethasone and methylprednisolone against cisplatin-induced ototoxicity. J. Laryngol. Otol. 2016, 130, 225–234. [Google Scholar] [CrossRef]
- Wikström, A.C.; Bakke, O.; Okret, S.; Brönnegård, M.; Gustafsson, J.A. Intracellular Localization of the Glucocorticoid Receptor: Evidence for Cytoplasmic and Nuclear Localization. Endocrinology 1987, 120, 1232–1242. [Google Scholar] [CrossRef]
- Borden, R.C.; Saunders, J.E.; Berryhill, W.E.; Krempl, G.A.; Thompson, D.M.; Queimado, L. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane. Audiol. Neurootol. 2010, 16, 1–11. [Google Scholar] [CrossRef]
- Lajud, S.A.; Han, Z.; Chi, F.L.; Gu, R.; Nagda, D.A.; Bezpalko, O.; Sanyal, S.; Bur, A.; Han, Z.; O’Malley, B.W.; et al. A regulated delivery system for inner ear drug application. J. Control. Release 2013, 166, 268–276. [Google Scholar] [CrossRef] [PubMed]
- Musazzi, U.M.; Franzé, S.; Cilurzo, F. Innovative pharmaceutical approaches for the management of inner ear disorders. Drug Deliv. Transl. Res. 2018, 8, 436–449. [Google Scholar] [CrossRef] [PubMed]
- Mäder, K.; Lehner, E.; Liebau, A.; Plontke, S.K. Controlled drug release to the inner ear: Concepts, materials, mechanisms, and performance. Hear. Res. 2018, 368, 49–66. [Google Scholar] [CrossRef] [PubMed]
- Du, X.; Cai, Q.; West, M.B.; Youm, I.; Huang, X.; Li, W.; Cheng, W.; Nakmali, D.; Ewert, D.L.; Kopke, R.D. Regeneration of Cochlear Hair Cells and Hearing Recovery through Hes1 Modulation with siRNA Nanoparticles in Adult Guinea Pigs. Mol. Ther. 2018, 26, 1313–1326. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martín-Saldaña, S.; Palao-Suay, R.; Trinidad, A.; Aguilar, M.R.; Ramírez-Camacho, R.; San Román, J. Otoprotective properties of 6α-methylprednisolone-loaded nanoparticles against cisplatin: In vitro and in vivo correlation. Nanomedicine 2016, 12, 965–976. [Google Scholar] [CrossRef] [PubMed]
- Martín-Saldaña, S.; Palao-Suay, R.; Aguilar, M.R.; Ramírez-Camacho, R.; San Román, J. Polymeric nanoparticles loaded with dexamethasone or α-tocopheryl succinate to prevent cisplatin-induced ototoxicity. Acta. Biomater. 2017, 53, 199–210. [Google Scholar] [CrossRef] [PubMed]
- Martín-Saldaña, S.; Palao-Suay, R.; Aguilar, M.R.; García-Fernández, L.; Arévalo, H.; Trinidad, A.; Ramírez-Camacho, R.; San Román, J. pH-sensitive polymeric nanoparticles with antioxidant and anti-inflammatory properties against cisplatin-induced hearing loss. J. Control. Release. 2018, 270, 53–64. [Google Scholar] [CrossRef] [PubMed]
- Dawoud, M.Z.; Nasr, M. Comparison of drug release from liquid crystalline monoolein dispersions and solid lipid nanoparticles using a flow cytometric technique. Acta. Pharm. Sin. B 2016, 6, 163–169. [Google Scholar] [CrossRef] [Green Version]
- Teixeira, M.C.; Carbone, C.; Souto, E.B. Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble/poorly permeable drug delivery. Prog. Lipid. Res. 2017, 68, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 2018, 10, 57. [Google Scholar] [CrossRef]
- Arana, L.; Salado, C.; Vega, S.; Aizpurua-Olaizola, O.; de la Arada, I.; Suarez, T.; Usobiaga, A.; Arrondo, J.L.R.; Alonso, A.; Goñi, F.M.; et al. Solid lipid nanoparticles for delivery of Calendula officinalis extract. Colloids Surf. B Biointerfaces 2015, 135, 18–26. [Google Scholar] [CrossRef] [PubMed]
- Arana, L.; Bayón-Cordero, L.; Sarasola, L.; Berasategi, M.; Ruiz, S.; Alkorta, I. Solid Lipid Nanoparticles Surface Modification Modulates Cell Internalization and Improves Chemotoxic Treatment in an Oral Carcinoma Cell Line. Nanomaterials 2019, 9, 464. [Google Scholar] [CrossRef] [PubMed]
- Raza, A.; Sime, F.B.; Cabot, P.J.; Maqbool, F.; Roberts, J.A.; Falconer, J.R. Solid nanoparticles for oral antimicrobial drug delivery: A review. Drug Discov. Today 2019, 24, 858–866. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Xiao, B.; Wang, H.; Han, M.K.; Zhang, Z.; Viennois, E.; Xu, C.; Merlin, D. Edible Ginger-derived Nano-lipids Loaded with Doxorubicin as a Novel Drug-delivery Approach for Colon Cancer Therapy. Mol. Ther. 2016, 24, 1783–1796. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serpe, L.; Catalano, M.G.; Cavalli, R.; Ugazio, E.; Bosco, O.; Canaparo, R.; Muntoni, E.; Frairia, R.; Gasco, M.R.; Eandi, M.; et al. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm. 2004, 58, 673–680. [Google Scholar] [CrossRef] [PubMed]
- Cavalli, R.; Peira, E.; Caputo, O.; Gasco, M.R. Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with beta-cyclodextrins. Int. J. Pharm. 1999, 182, 59–69. [Google Scholar] [CrossRef]
- Marengo, E.; Cavalli, R.; Caputo, O.; Rodriguez, L.; Gasco, M.R. Scale-up of the preparation process of solid lipid nanospheres. Part I. Int. J. Pharm. 2000, 205, 3–13. [Google Scholar] [CrossRef]
- Shegokar, R.; Müller, R.H. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 2010, 399, 129–139. [Google Scholar] [CrossRef]
- Howard, M.D.; Lu, X.; Jay, M.; Dziubla, T.D. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles. Drug Dev. Ind. Pharm. 2012, 38, 1270–1279. [Google Scholar] [CrossRef]
- Lau, E.T.L.; Giddings, S.J.; Mohammed, S.G.; Dubois, P.; Johnson, S.K.; Stanley, R.A.; Halley, P.J.; Steadman, K.J. Encapsulation of hydrocortisone and mesalazine in zein microparticles. Pharmaceutics 2013, 5, 277–293. [Google Scholar] [CrossRef]
- Kalinec, G.M.; Park, C.; Thein, P.; Kalinec, F. Working with Auditory HEI-OC1 Cells. J. Vis. Exp. 2016, 115, e54425. [Google Scholar] [CrossRef] [PubMed]
- Yin, H.; Sun, G.; Yang, Q.; Chen, C.; Qi, Q.; Wang, H.; Li, J. NLRX1 accelerates cisplatin-induced ototoxity in HEI-OC1 cells via promoting generation of ROS and activation of JNK signaling pathway. Sci. Rep. 2017, 7, 44311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Singh, R.; Lillard, J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86, 215–223. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haynes, D.S.; O’Malley, M.; Cohen, S.; Watford, K.; Labadie, R.F. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope 2007, 117, 3–15. [Google Scholar] [CrossRef] [PubMed]
- Meltser, I.; Canlon, B. Protecting the auditory system with glucocorticoids. Hear. Res. 2011, 281, 47–55. [Google Scholar] [CrossRef] [PubMed]
- Gensler, L.S. Glucocorticoids: Complications to Anticipate and Prevent. Neurohospitalist 2013, 3, 92–97. [Google Scholar] [CrossRef] [PubMed]
- Stahn, C.; Buttgereit, F. Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pr. Rheumatol. 2008, 4, 525–533. [Google Scholar] [CrossRef]
- Gul, F.; Muderris, T.; Yalciner, G.; Sevil, E.; Bercin, S.; Ergin, M.; Babademez, M.A.; Kiris, M. A comprehensive study of oxidative stress in sudden hearing loss. Eur. Arch. Otorhinolaryngol. 2017, 274, 1301–1308. [Google Scholar] [CrossRef]
- Okano, T. Immune system of the inner ear as a novel therapeutic target for sensorineural hearing loss. Front. Pharmacol. 2014, 5, 205. [Google Scholar] [CrossRef] [Green Version]
- Metrailer, A.M.; Babu, S.C. Management of sudden sensorineural hearing loss. Curr. Opin. Otolaryngol. Head Neck Surg. 2016, 24, 403–406. [Google Scholar] [CrossRef]
- Murillo-Cuesta, S.; Vallecillo, N.; Cediel, R.; Celaya, A.M.; Lassaletta, L.; Varela-Nieto, I.; Contreras, J. A Comparative Study of Drug Delivery Methods Targeted to the Mouse Inner Ear: Bullostomy Versus Transtympanic Injection. J. Vis. Exp. 2017, 121, e54951. [Google Scholar] [CrossRef] [PubMed]
- Plontke, S.K.; Götze, G.; Rahne, T.; Liebau, A. Intracochlear drug delivery in combination with cochlear implants: Current aspects. HNO 2017, 65, 19–28. [Google Scholar] [CrossRef] [PubMed]
- Yang, K.J.; Son, J.; Jung, S.Y.; Yi, G.; Yoo, J.; Kim, D.K.; Koo, H. Optimized phospholipid-based nanoparticles for inner ear drug delivery and therapy. Biomaterials 2018, 171, 133–143. [Google Scholar] [CrossRef] [PubMed]
- Mehnert, W.; Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47, 165–196. [Google Scholar] [CrossRef]
- Wissing, S.A.; Kayser, O.; Müller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv. Rev. 2004, 56, 1257–1272. [Google Scholar] [CrossRef] [PubMed]
- Geszke-Moritz, M.; Moritz, M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties and therapeutic strategies. Mater. Sci. Eng. C 2016, 68, 982–994. [Google Scholar] [CrossRef]
- Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J. Control. Release. 2017, 264, 306–332. [Google Scholar] [CrossRef]
- Shah, R.; Eldridge, D.; Palombo, E.; Harding, I. Optimisation and Stability Assessment of Solid Lipid Nanoparticles using Particle Size and Zeta Potential. J. Phys. Sci. 2014, 25, 59–75. [Google Scholar]
- Gao, G.; Liu, Y.; Zhou, C.H.; Jiang, P.; Sun, J.J. Solid Lipid Nanoparticles Loaded with Edaravone for Inner Ear Protection After Noise Exposure. Chin. Med. J. 2015, 128, 203. [Google Scholar] [CrossRef]
- Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release. 2010, 148, 135–146. [Google Scholar] [CrossRef]
- Bowe, S.N.; Jacob, A. Round window perfusion dynamics: Implications for intracochlear therapy. Curr. Opin. Otolaryngol. Head Neck Surg. 2010, 18, 377–385. [Google Scholar] [CrossRef] [PubMed]
- Cai, H.; Liang, Z.; Huang, W.; Wen, L.; Chen, G. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery. Int. J. Pharm. 2017, 532, 55–65. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Zhang, W.; Löbler, M.; Schmitz, K.P.; Saulnier, P.; Perrier, T.; Pyykkö, I.; Zou, J. Inner ear biocompatibility of lipid nanocapsules after round window membrane application. Int. J. Pharm. 2011, 404, 211–219. [Google Scholar] [CrossRef] [PubMed]
- Sun, C.; Wang, X.; Zheng, Z.; Chen, D.; Wang, X.; Shi, F.; Yu, D.; Wu, H. A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration. Int. J. Nanomed. 2015, 10, 3567–3579. [Google Scholar]
- Müller, R.H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - A review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50, 161–177. [Google Scholar] [CrossRef]
- Bu, M.; Tang, J.; Wei, Y.; Sun, Y.; Wang, X.; Wu, L.; Liu, H. Enhanced bioavailability of nerve growth factor with phytantriol lipid-based crystalline nanoparticles in cochlea. Int. J. Nanomed. 2015, 10, 6879–6889. [Google Scholar] [Green Version]
- Valente, F.; Bysell, H.; Simoni, E.; Boge, L.; Eriksson, M.; Martini, A.; Astolfi, L. Evaluation of toxicity of glycerol monooleate nanoparticles on PC12 cell line. Int. J. Pharm. 2018, 539, 23–30. [Google Scholar] [CrossRef]
- Kalinec, G.; Thein, P.; Park, C.; Kalinec, F. HEI-OC1 cells as a model for investigating drug cytotoxicity. Hear. Res. 2016, 335, 105–117. [Google Scholar] [CrossRef]
- Dinh, C.T.; Chen, S.; Bas, E.; Dinh, J.; Goncalves, S.; Telischi, F.; Angeli, S.; Eshraghi, A.A.; Van De Water, T. Dexamethasone Protects Against Apoptotic Cell Death of Cisplatin-exposed Auditory Hair Cells In Vitro. Otol. Neurotol. 2015, 36, 1566–1571. [Google Scholar] [CrossRef]
- Creber, N.J.; Eastwood, H.T.; Hampson, A.J.; Tan, J.; O’Leary, S.J. A comparison of cochlear distribution and glucocorticoid receptor activation in local and systemic dexamethasone drug delivery regimes. Hear. Res. 2018, 368, 75–85. [Google Scholar] [CrossRef]
- Lyu, A.R.; Kim, D.H.; Lee, S.H.; Shin, D.S.; Shin, S.A.; Park, Y.H. Effects of dexamethasone on intracochlear inflammation and residual hearing after cochleostomy: A comparison of administration routes. PLoS ONE 2018, 13, e0195230. [Google Scholar] [CrossRef] [PubMed]
- Rhen, T.; Cidlowski, J.A. Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs. N. Engl. J. Med. 2005, 353, 1711–1723. [Google Scholar] [CrossRef] [PubMed]
- Pelt, A.C. Glucocorticoids: Effects, Action Mechanisms, and Therapeutic Uses; Nova Science: Hauppauge, NY, USA, 2011; ISBN 161728758X. [Google Scholar]
- El Kechai, N.; Mamelle, E.; Nguyen, Y.; Huang, N.; Nicolas, V.; Chaminade, P.; Yen-Nicolaÿ, S.; Gueutin, C.; Granger, B.; Ferrary, E.; et al. Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear. J. Control. Release. 2016, 226, 248–257. [Google Scholar] [CrossRef] [PubMed]
- Sun, C.; Wang, X.; Chen, D.; Lin, X.; Yu, D.; Wu, H. Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration. Neurosci. Lett. 2016, 619, 142–148. [Google Scholar] [CrossRef] [PubMed]
Nanoparticle | Particle Size ± SD (nm) | pdi ± SD | ζ-potential ± SD (mV) | ||||
---|---|---|---|---|---|---|---|
Storage (Month) | 0 | 8 | 0 | 8 | 0 | 8 | |
SLN | 99.00 ± 4.96 | 94.03 ± 6.13 | 0.309 ± 0.05 | 0.333 ± 0.031 | −45.3 ± 1.82 | −41.81 ± 1.88 | |
SLN–DEX | 100.69 ± 10.23 | 117.98 ± 5.70 | 0.299 ± 0.03 | 0.278 ± 0.009 | −44.3 ± 1.09 | −46.00 ± 2.83 | |
SLN–HC | 101.91 ± 2.19 | 124.33 ± 9.01 | 0.288 ± 0.05 | 0.232 ± 0.016 | −44.8 ± 1.58 | −44.38 ± 3.48 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cervantes, B.; Arana, L.; Murillo-Cuesta, S.; Bruno, M.; Alkorta, I.; Varela-Nieto, I. Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity. J. Clin. Med. 2019, 8, 1464. https://doi.org/10.3390/jcm8091464
Cervantes B, Arana L, Murillo-Cuesta S, Bruno M, Alkorta I, Varela-Nieto I. Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity. Journal of Clinical Medicine. 2019; 8(9):1464. https://doi.org/10.3390/jcm8091464
Chicago/Turabian StyleCervantes, Blanca, Lide Arana, Silvia Murillo-Cuesta, Marina Bruno, Itziar Alkorta, and Isabel Varela-Nieto. 2019. "Solid Lipid Nanoparticles Loaded with Glucocorticoids Protect Auditory Cells from Cisplatin-Induced Ototoxicity" Journal of Clinical Medicine 8, no. 9: 1464. https://doi.org/10.3390/jcm8091464